Immunohistochemical validation via the Human Protein Atlas confirmed elevated TIMP1 protein levels in CRC, breast cancer, glioma, hepatocellular carcinoma, and gastric adenocarcinoma (Figure 7C), underscoring its pan-cancer relevance. This evidence concerns the gene TIMP1 and breast carcinoma.